Today the French Ministry of Health authorised wide reimbursement of Spinraza. Now every SMA patient in France will be able to receive life-saving treatment.
So I guess our silence is fairly obvious. We have heard nothing from NICE, not a single word.
Avexis, the company behind gene replacement therapy AVXS-101, disclosed preliminary data from their phase-3 clinical trial of intravenous AVXS-101 (Zolgensma). The effects are simply breathtaking!